Evaluation of Mediators Associated with the Inflammatory Response in Prostate Cancer Patients Undergoing Radiotherapy

Autor: Sergio Villa, Paola Allavena, Riccardo Valdagni, Valentina Zuco, Nice Bedini, Elisa Campi, Alessandro Cicchetti, Federica Palorini, Samantha Pesce, S. Morlino, Nadia Zaffaroni, Barbara Avuzzi, Tiziana Rancati, Maria Emanuela Visentin, Tiziana Magnani, Marzia Pennati
Jazyk: angličtina
Rok vydání: 2018
Předmět:
0301 basic medicine
Oncology
Male
medicine.medical_specialty
Chemokine
Article Subject
medicine.medical_treatment
Clinical Biochemistry
CCL2
03 medical and health sciences
Basal (phylogenetics)
Prostate cancer
0302 clinical medicine
Internal medicine
Genetics
medicine
Biomarkers
Tumor
Humans
Radiation Injuries
Molecular Biology
Chemokine CCL2
Aged
lcsh:R5-920
biology
business.industry
Interleukin-6
Tumor Necrosis Factor-alpha
Biochemistry (medical)
Interleukin-8
Prostatic Neoplasms
General Medicine
PTX3
Middle Aged
medicine.disease
Radiation therapy
Serum Amyloid P-Component
030104 developmental biology
C-Reactive Protein
030220 oncology & carcinogenesis
biology.protein
Clinical Study
Tumor necrosis factor alpha
Radiotherapy
Intensity-Modulated
lcsh:Medicine (General)
business
Abdominal surgery
Interleukin-1
Zdroj: Disease Markers
Disease Markers, Vol 2018 (2018)
ISSN: 1875-8630
0278-0240
Popis: A recent “hot topic” in prostate cancer radiotherapy is the observed association between acute/late rectal toxicity and the presence of abdominal surgery before radiotherapy. The exact mechanism is unclear. Our working hypothesis was that a previous surgery may influence plasma level of inflammatory molecules and this might result in enhanced radiosensitivity. We here present results on the feasibility of monitoring the expression of inflammatory molecules during radiotherapy. Plasma levels of a panel of soluble mediators associated with the inflammatory response were measured in prostate cancer patients undergoing radical radiotherapy. We measured 3 cytokines (IL-1b, IL-6, and TNF alpha), 2 chemokines (CCL2 and CXCL8), and the long pentraxin PTX3. 20 patients were enrolled in this feasibility evaluation. All patients were treated with IMRT at 78 Gy. 3/20 patients reported grade 2 acute rectal toxicity, while 4/20 were scored as grade 2 late toxicity. CCL2 was the most interesting marker showing significant increase during and after radiotherapy. CCL2 levels at radiotherapy end could be modelled using linear regression including basal CCL2, age, surgery, hypertension, and use of anticoagulants. The 4 patients with late toxicity had CCL2 values at radiotherapy end above the median value. This trial is registered with ISRCTN64979094.
Databáze: OpenAIRE
Externí odkaz: